[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1221646A1 - 高劑量普利多匹定用於治療亨廷頓舞蹈症的用途 - Google Patents

高劑量普利多匹定用於治療亨廷頓舞蹈症的用途

Info

Publication number
HK1221646A1
HK1221646A1 HK16109788.9A HK16109788A HK1221646A1 HK 1221646 A1 HK1221646 A1 HK 1221646A1 HK 16109788 A HK16109788 A HK 16109788A HK 1221646 A1 HK1221646 A1 HK 1221646A1
Authority
HK
Hong Kong
Prior art keywords
treating
high dose
huntingtons disease
dose pridopidine
pridopidine
Prior art date
Application number
HK16109788.9A
Other languages
English (en)
Inventor
Bassan Merav
Eyal Eli
Lukasiewicz Hagai Esther
Kristina Sveinsdotter Teige Wickenberg Anna
Original Assignee
Teva Pharmaceuticals Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52105289&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1221646(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceuticals Int Gmbh filed Critical Teva Pharmaceuticals Int Gmbh
Publication of HK1221646A1 publication Critical patent/HK1221646A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK16109788.9A 2013-06-21 2016-08-16 高劑量普利多匹定用於治療亨廷頓舞蹈症的用途 HK1221646A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361837928P 2013-06-21 2013-06-21
US201361877832P 2013-09-13 2013-09-13
PCT/US2014/043204 WO2014205229A1 (en) 2013-06-21 2014-06-19 Use of high dose pridopidine for treating huntington's disease

Publications (1)

Publication Number Publication Date
HK1221646A1 true HK1221646A1 (zh) 2017-06-09

Family

ID=52105289

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16109788.9A HK1221646A1 (zh) 2013-06-21 2016-08-16 高劑量普利多匹定用於治療亨廷頓舞蹈症的用途

Country Status (24)

Country Link
US (1) US10322119B2 (zh)
EP (1) EP3010506B1 (zh)
JP (1) JP2016523862A (zh)
KR (1) KR102316933B1 (zh)
CN (1) CN105592848A (zh)
AU (1) AU2014281414A1 (zh)
BR (1) BR112015029918A2 (zh)
CA (1) CA2913781C (zh)
CL (1) CL2015003690A1 (zh)
DK (1) DK3010506T3 (zh)
EA (1) EA201690069A1 (zh)
ES (1) ES2879631T3 (zh)
HK (1) HK1221646A1 (zh)
HU (1) HUE054783T2 (zh)
IL (1) IL242804B (zh)
MX (1) MX2015017307A (zh)
PE (2) PE20160195A1 (zh)
PH (1) PH12015502691A1 (zh)
PL (1) PL3010506T3 (zh)
SG (1) SG11201509729YA (zh)
TW (1) TW201529069A (zh)
UA (1) UA122999C2 (zh)
UY (1) UY35624A (zh)
WO (1) WO2014205229A1 (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
WO2012028635A1 (en) 2010-09-03 2012-03-08 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Deuterated analogs of pridopidine useful as dopaminergic stabilizers
EP2787997A4 (en) 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
JP6949487B2 (ja) * 2014-01-22 2021-10-13 プリレニア・ニューロセラピューティクス・エルティーディーＰｒｉｌｅｎｉａ Ｎｅｕｒｏｔｈｅｒａｐｅｕｔｉｃｓ Ｌｔｄ プリドピジンの調節放出製剤
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
JP2018505147A (ja) 2014-12-22 2018-02-22 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー プリドピジンのｌ−酒石酸塩
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
WO2016138130A1 (en) * 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Use of pridopidine to improve cognitive function and for treating alzheimer's disease
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
US20170020854A1 (en) * 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
WO2017147366A1 (en) 2016-02-24 2017-08-31 Teva Pharmaceuticals International Gmbh Treatment of neurodegenerative eye disease using pridopidine
EP3503890A4 (en) * 2016-08-24 2020-05-06 Prilenia Neurotherapeutics Ltd. USE OF PRIDOPIDINE FOR THE TREATMENT OF DYSTONIA
IL311081A (en) * 2016-08-24 2024-04-01 Prilenia Neurotherapeutics Ltd Use of pyridofidine to treat functional decline
EP3512517A4 (en) * 2016-09-15 2020-05-06 Prilenia Neurotherapeutics Ltd. USE OF PRIDOPIDIN FOR THE TREATMENT OF ANXIETY AND DEPRESSION
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
DK3512506T3 (da) 2016-09-16 2022-04-19 Prilenia Neurotherapeutics Ltd Anvendelse af pridopidin til behandling af retts syndrom
DK3570940T3 (da) 2017-01-20 2024-02-19 Prilenia Neurotherapeutics Ltd Pridopidin til anvendelse i behandling af fragilt x-syndrom
EA202090510A1 (ru) * 2017-08-14 2020-06-08 Приления Ньюротерапьютикс Лтд. Способ лечения бокового амиотрофического склероза придопидином
EP3675830A1 (en) * 2017-08-30 2020-07-08 Prilenia Neurotherapeutics Ltd. High concentration dosage forms of pridopidine
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
EP3678664A1 (en) 2017-09-08 2020-07-15 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
CA3137633A1 (en) * 2019-06-12 2020-12-17 Prilenia Neurotherapeutics Ltd. Composition comprising pridopidine and analog thereof for treating huntington disease and symptoms thereof
EP4030993A4 (en) * 2019-09-17 2023-10-25 F. Hoffmann-La Roche AG IMPROVEMENTS IN PERSONALIZED HEALTH CARE FOR PATIENTS WITH MOTOR DISORDERS
US20230390232A1 (en) * 2020-10-28 2023-12-07 Buck Institute For Research On Aging N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating the pathogenesis of neurodegenerative disorders

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
EP1713486A4 (en) 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
AU2005293754B2 (en) 2004-10-13 2011-07-21 Teva Pharmaceuticals International Gmbh Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-N-propyl-piperidine
EP1815857A1 (en) * 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
CA2683719C (en) 2007-04-12 2015-07-14 Nsab, Filial Af Neurosearch Sweden Ab, Sverige N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
WO2010008486A2 (en) 2008-06-24 2010-01-21 Parkinsons Institute Pluripotent cell lines and methods of use thereof
US8384755B2 (en) 2009-08-26 2013-02-26 Intouch Technologies, Inc. Portable remote presence robot
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
WO2012028635A1 (en) 2010-09-03 2012-03-08 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Deuterated analogs of pridopidine useful as dopaminergic stabilizers
BR112014005389A8 (pt) * 2011-09-07 2018-04-03 Ivax Int Gmbh Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal
EP2787997A4 (en) 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
EP2844346B1 (en) 2012-04-04 2020-01-01 Prilenia Neurotherapeutics Ltd. Pharmaceutical compositions for combination therapy
BR112015006093A2 (pt) 2012-09-27 2017-07-04 Teva Pharma combinação de rasagilina e pridopidine para o tratamento de desordens neurodegenerativas, particularmente na doença de huntington
US20150209346A1 (en) 2012-09-27 2015-07-30 Teva Pharmaceutical Industries, Ltd. Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
JP6949487B2 (ja) 2014-01-22 2021-10-13 プリレニア・ニューロセラピューティクス・エルティーディーＰｒｉｌｅｎｉａ Ｎｅｕｒｏｔｈｅｒａｐｅｕｔｉｃｓ Ｌｔｄ プリドピジンの調節放出製剤
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
JP2018505147A (ja) 2014-12-22 2018-02-22 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー プリドピジンのｌ−酒石酸塩
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
WO2016138130A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Use of pridopidine to improve cognitive function and for treating alzheimer's disease
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
US20170020854A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
WO2017048457A1 (en) 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
EP3503890A4 (en) 2016-08-24 2020-05-06 Prilenia Neurotherapeutics Ltd. USE OF PRIDOPIDINE FOR THE TREATMENT OF DYSTONIA
IL311081A (en) * 2016-08-24 2024-04-01 Prilenia Neurotherapeutics Ltd Use of pyridofidine to treat functional decline
EP3512517A4 (en) 2016-09-15 2020-05-06 Prilenia Neurotherapeutics Ltd. USE OF PRIDOPIDIN FOR THE TREATMENT OF ANXIETY AND DEPRESSION
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
DK3512506T3 (da) 2016-09-16 2022-04-19 Prilenia Neurotherapeutics Ltd Anvendelse af pridopidin til behandling af retts syndrom

Also Published As

Publication number Publication date
WO2014205229A8 (en) 2015-04-09
US20140378508A1 (en) 2014-12-25
BR112015029918A2 (pt) 2017-07-25
DK3010506T3 (da) 2021-07-12
EP3010506A4 (en) 2017-02-08
TW201529069A (zh) 2015-08-01
SG11201509729YA (en) 2015-12-30
PH12015502691A1 (en) 2016-03-14
WO2014205229A1 (en) 2014-12-24
US10322119B2 (en) 2019-06-18
EA201690069A1 (ru) 2016-06-30
ES2879631T3 (es) 2021-11-22
PE20170302A1 (es) 2017-03-31
AU2014281414A1 (en) 2016-01-21
KR20160055122A (ko) 2016-05-17
CL2015003690A1 (es) 2016-10-28
UA122999C2 (uk) 2021-02-03
HUE054783T2 (hu) 2021-09-28
IL242804B (en) 2022-02-01
PL3010506T3 (pl) 2021-11-02
MX2015017307A (es) 2016-08-03
JP2016523862A (ja) 2016-08-12
CA2913781A1 (en) 2014-12-24
CN105592848A (zh) 2016-05-18
CA2913781C (en) 2022-05-10
UY35624A (es) 2015-01-30
PE20160195A1 (es) 2016-05-14
EP3010506A1 (en) 2016-04-27
KR102316933B1 (ko) 2021-10-26
EP3010506B1 (en) 2021-05-12

Similar Documents

Publication Publication Date Title
HK1221646A1 (zh) 高劑量普利多匹定用於治療亨廷頓舞蹈症的用途
IL243976A0 (en) kdm1a inhibitors for disease treatment
HK1225305A1 (zh) 治療腦疾病的方法和組合物
IL241232A0 (en) Cancer treatment agents
EP2968348A4 (en) COMPOUNDS FOR THE TREATMENT OF CANCER
EP3019491A4 (en) KINASE INHIBITORS FOR THE TREATMENT OF DISEASE
EP2958936A4 (en) METHOD AND COMPOSITIONS FOR TREATING CORI DISEASE
HK1220324A1 (zh) 用於治療血管緊張素相關疾病的方法、化合物和組合物
HK1219653A1 (zh) 治療線粒體疾病的方法
IL244353A0 (en) Compounds and use for cancer treatment
HK1213817A1 (zh) 治療癌症的方法
HK1222548A1 (zh) 治療惡性腫瘤的藥物組合
HK1219737A1 (zh) 用於治療癌症的新化合物
HK1223547A1 (zh) 癌症治療方法
HK1219513A1 (zh) 治療癌症的方法
GB201403083D0 (en) Treatment of cancer
EP2986294A4 (en) COMPOUNDS FOR THE TREATMENT OF PAIN
GB201308466D0 (en) Improved process for treatment of minewater
HK1232118A1 (zh) 癌症的治療
GB201307348D0 (en) Garment for therapeutic treatment
HK1224215A1 (zh) 高劑量普利多匹定用於治療亨廷頓舞蹈症的用途
PL3016948T3 (pl) 2-acyloaminotiazole do leczenia nowotworów
EP2986295A4 (en) COMPOUNDS FOR THE TREATMENT OF PAIN
GB201321628D0 (en) Treatment of disease
GB201322347D0 (en) Treatment of cancer